Fidson Healthcare Past Earnings Performance
Past criteria checks 2/6
Fidson Healthcare has been growing earnings at an average annual rate of 49.8%, while the Pharmaceuticals industry saw earnings growing at 6.4% annually. Revenues have been growing at an average rate of 28.9% per year. Fidson Healthcare's return on equity is 18.7%, and it has net margins of 6.8%.
Key information
49.8%
Earnings growth rate
47.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 21.6% |
| Revenue growth rate | 28.9% |
| Return on equity | 18.7% |
| Net Margin | 6.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Fidson Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 53,050 | 3,608 | 12,029 | 0 |
| 30 Sep 23 | 49,580 | 4,318 | 10,771 | 0 |
| 30 Jun 23 | 45,835 | 4,255 | 11,258 | 0 |
| 31 Mar 23 | 41,795 | 4,399 | 10,391 | 0 |
| 31 Dec 22 | 40,634 | 4,187 | 9,538 | 0 |
| 30 Sep 22 | 40,486 | 4,835 | 11,407 | 0 |
| 30 Jun 22 | 38,311 | 5,233 | 10,913 | 0 |
| 31 Mar 22 | 34,751 | 4,290 | 10,349 | 0 |
| 31 Dec 21 | 30,861 | 3,720 | 9,534 | 0 |
| 30 Sep 21 | 26,431 | 2,553 | 8,044 | 0 |
| 30 Jun 21 | 23,000 | 1,894 | 7,373 | 0 |
| 31 Mar 21 | 20,878 | 1,633 | 6,021 | 0 |
| 31 Dec 20 | 18,276 | 1,205 | 5,481 | 0 |
| 30 Sep 20 | 17,234 | 1,111 | 4,993 | 0 |
| 30 Jun 20 | 14,896 | 630 | 3,848 | 0 |
| 31 Mar 20 | 14,276 | 414 | 3,858 | 0 |
| 31 Dec 19 | 14,062 | 407 | 3,633 | 0 |
| 30 Sep 19 | 15,259 | -605 | 3,842 | 0 |
| 30 Jun 19 | 16,169 | -358 | 3,989 | 0 |
| 31 Mar 19 | 16,157 | -155 | 3,932 | 0 |
| 31 Dec 18 | 16,230 | -97 | 4,031 | 0 |
| 30 Sep 18 | 15,201 | 1,111 | 4,151 | 0 |
| 30 Jun 18 | 14,824 | 1,132 | 4,233 | 0 |
| 31 Mar 18 | 14,246 | 1,103 | 4,145 | 0 |
| 31 Dec 17 | 14,057 | 1,061 | 4,341 | 0 |
| 30 Sep 17 | 13,431 | 965 | 4,501 | 0 |
| 30 Jun 17 | 10,532 | 715 | 3,516 | 0 |
| 31 Mar 17 | 9,859 | 449 | 3,631 | 0 |
| 31 Dec 16 | 7,655 | 317 | 2,784 | 0 |
| 30 Sep 16 | 6,577 | 353 | 2,295 | 0 |
| 30 Jun 16 | 7,966 | 488 | 2,467 | 0 |
| 31 Mar 16 | 8,199 | 731 | 2,614 | 0 |
| 31 Dec 15 | 8,211 | 744 | 2,671 | 0 |
| 30 Sep 15 | 8,370 | 639 | 2,565 | 0 |
| 30 Jun 15 | 9,186 | 646 | 3,740 | 0 |
| 31 Mar 15 | 8,255 | 470 | 3,486 | 0 |
| 31 Dec 14 | 9,719 | 632 | 3,716 | 0 |
| 30 Sep 14 | 9,517 | 240 | 4,471 | 0 |
| 30 Jun 14 | 9,134 | 167 | 4,340 | 0 |
| 31 Mar 14 | 9,322 | 164 | 4,413 | 0 |
| 31 Dec 13 | 9,247 | 155 | 4,503 | 0 |
| 30 Sep 13 | 8,845 | 352 | 2,936 | 0 |
| 30 Jun 13 | 8,264 | 357 | 2,936 | 0 |
Quality Earnings: FIDSON has high quality earnings.
Growing Profit Margin: FIDSON's current net profit margins (6.8%) are lower than last year (10.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FIDSON has become profitable over the past 5 years, growing earnings by 49.8% per year.
Accelerating Growth: FIDSON's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: FIDSON had negative earnings growth (-13.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.4%).
Return on Equity
High ROE: FIDSON's Return on Equity (18.7%) is considered low.